San Francisco startup Framework Therapeutics can be working on an oral, the moment-daily GLP-1 drug known as GSBR-1290—the drug surpassed Wall Street’s anticipations in June whenever a mid-phase examine showed normal weight loss of all over 6% and it designs to begin Yet another mid-stage demo toward the tip of this 12 months—that founder and… Read More